Tvardi Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
Tvardi Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for TTI-101 in Head and Neck Squamous Cell Carcinoma (Approved) using Small Molecule.
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| Who We Are | n/a | Small Molecule | n/a | Public pipeline row |
| January 8, 2026 | n/a | n/a | Phase 2 | Public pipeline row |
| TTI-101 | Head and Neck Squamous Cell Carcinoma | n/a | Approved | Public pipeline row |
| TTI-109 | n/a | n/a | Phase 1 | Public pipeline row |
| TTI-109 in Healthy Volunteers (Currently Recruiting) | n/a | n/a | Phase 2 | Public pipeline row |
| Control Group | Squamous Cell Carcinoma of Head and Neck | n/a | Early_Phase 1 | Public pipeline row |
No public catalyst rows matched this view yet.
Estimated cash runway: Runway > 12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT05668949 | Phase 1 | Phase 2 | WITHDRAWN | n/a | 2025-09-23 |
| NCT05845307 | Early_Phase 1 | WITHDRAWN | n/a | 2025-11-13 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.